Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VNDA
VNDA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VNDA News
Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
3d ago
PRnewswire
Vanda Pharmaceuticals Q1 2026 Earnings Call Highlights
3d ago
seekingalpha
Vanda Pharmaceuticals Q1 2026 Earnings Report
4d ago
seekingalpha
Vanda Pharmaceuticals Launches Nereus™ (Tradipitant), the First New Medication for Motion Sickness in Over 40 Years, Now Available in the U.S.
6d ago
moomoo
Vanda Pharmaceuticals Launches NEREUS, First New Motion Sickness Drug in 40 Years
6d ago
NASDAQ.COM
Vanda's Nereus Drug Approved by FDA for Motion Sickness
May 01 2026
stocktwits
Vanda Pharmaceuticals Launches Nereus for Motion Sickness
May 01 2026
seekingalpha
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Treatment
May 01 2026
Newsfilter
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Relief
May 01 2026
PRnewswire
Vanda Pharmaceuticals to Release Q1 2026 Financial Results
Apr 29 2026
PRnewswire
Vanda Pharmaceuticals to Release Q1 2026 Results on May 6
Apr 29 2026
Newsfilter
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings
Apr 28 2026
PRnewswire
Vanda Pharmaceuticals Announces Imsidolimab Research Findings
Apr 28 2026
Newsfilter
Vanda Pharmaceuticals Appoints New Board Member
Apr 22 2026
PRnewswire
Vanda Pharmaceuticals Appoints New Board Member
Apr 22 2026
Newsfilter
ANAPTYS FINALIZES DIVESTITURE OF FIRST TRACKS BIOTHERAPEUTICS AND NOW FOCUSES SOLELY ON GSK AND VANDA FINANCIAL PARTNERSHIPS
Apr 20 2026
moomoo
Show More News
